Acumen Pharmaceuticals' Q1 2025: Key Contradictions in ALTITUDE Study and Strategic Outlook

Interim analysis in ALTITUDE study, importance of subcutaneous formulation, potential of plasma biomarkers in Alzheimer's disease, enrollment rate and outlook for ALTITUDE study, and the impact of commercial antibodies on the trial are the key contradictions discussed in Acumen Pharmaceuticals' latest 2025Q1 earnings call.



Study Enrollment and Progress:
- Acumen Pharmaceuticals completed enrollment of its 542-participant Phase 2 study, ALTITUDE-AD, much faster than expected, in roughly 10 months.
- This rapid enrollment was driven by interest in Sabirnetug's therapeutic potential, innovative participant screening methods, and strong team execution.

Innovative Biomarker Screening:
- The company reported an improvement in enrollment efficiency by using a plasma phospho-tau 217 screening procedure in ALTITUDE-AD.
- The use of this assay reduced patient burden, screening costs, and contributed to the rapid enrollment rate.

Financial Stability and R&D Investment:
- As of March 31, 2025, Acumen had $197.9 million in cash and marketable securities, expected to support operations into early 2027.
- The increased R&D expenses of $25.3 million in Q1 were primarily due to supporting the ALTITUDE-AD trial, reflecting the company's commitment to its clinical development programs.

Subcutaneous Administration of Sabirnetug:
- Acumen completed a Phase 1 study investigating subcutaneous administration of Sabirnetug, showing that it was well-tolerated with supportive systemic exposure.
- Continued development of this route of administration is planned, with future integration into the program depend on formulation and drug delivery assessments.